(Incorporated in the Republic of Singapore)
(Company Registration No. 200009059G)

ANNOUNCEMENT PURSUANT TO RULE 704(18)(a) OF THE LISTING MANUAL OF THE SINGAPORE EXCHANGE SECURITIES TRADING LIMITED ("SGX-ST")

The Board of Directors of mDR Limited (the "**Company**") refers to the Company's announcements dated 10 December 2019 and 2 May 2023 (the "**Announcements**"), in relation to the convertible loan agreement entered into between CytoMed Therapeutics Ltd ("**CytoMed**") and the Company.

Capitalised terms in this announcement (unless otherwise defined or the context otherwise requires) have the same meaning as ascribed to them in the Announcements.

Pursuant to Rule 704(18)(a) of the Mainboard Rules of the Listing Manual of the SGX-ST, the Company wishes to announce that on 12 October 2026, the Company sold 30,000 ordinary shares in CytoMed through market transactions on NASDAQ. Following the aforesaid sale, the Company's shareholding in CytoMed has decreased from approximately 10.23% to approximately 9.98% of CytoMed's total issued shares.

BY ORDER OF THE BOARD

Madan Mohan
Company Secretary

13 October 2026